Not registered yet? Please contact our project assistant Dennis Cleff . This area is only for members of the research consortium.


9 July 2024

Press release: COMBAT Trial – First patient enrolled

Barcelona, Spain, 9th July 2024 – DECISION, an EU-funded research consortium in liver disease research, is pleased to announce the enrollment of the first patient at Hôpital Beaujon, Clichy, France in the COMBAT Trial, a multicenter, randomized, open-label, Phase II clinical trial. This trial is a crucial component of the DECISION project, which aims to transform the treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF).

More information in our Press release.
Watch this video for more information on the COMBAT Trial, a lecture by Prof. Paolo Caraceni, Principal Investigator of the COMBAT Trial.

More news


2 July 2024

Liver International special edition on ACLF and AD: Sneak Peek #6

We’re continuing our series: Some partners of DECISION are currently preparing a special edition in Liver International on acute-on-chronic liver failure (ACLF) and acute decompensation (AD) of cirrhosis! ✨
As a sneak peek, we are excited to share some of the reviews and articles that will be cited in this special edition! (read reviews #1#2#3, #4, and #5 here)

The sixth review is:
Shantha R. Valainathan, Qing Xie, Vicente Arroyo, Pierre-Emmanuel Rautou: Prognosis algorithms for acute decompensation of cirrhosis and ACLF. Liver Int 2024.


🔑 Key points

  • CLIF-C AD score is a score developed and validated for patients with acute decompensation of cirrhosis without ACLF.
  • For patients with ACLF, three different scoring system are widely used, namely the CLIF-C ACLF score, the AARC score and the NACSELD score.
  • Predictive value of currently available scores can still be improved.
  • Multiomics analyses may help develop novel tools to improve prediction of patients outcome.
More news


5 - 8 June 2024

DECISION at EASL Congress 2024

What a blast! DECISION members have been super active at this year's EASL Congress 2024 in Milan, Italy. A highlight definitely was our networking event on 5th June 2024, with a packed cirrhosis and complications track hub.

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more